ReviewHealth affairs (Project Hope)2020
The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States.
Review in Health affairs (Project Hope), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
209 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Cost of the COVID-19 pandemic versus the cost-effectiveness of mitigation strategies in EU/UK/OECD: a systematic review.BMJ open · 2023Pooled it
- Effect of mobile application types on stroke rehabilitation: a systematic review.Journal of neuroengineering and rehabilitation · 2023Pooled it
- Mortality rate and predictors of COVID-19 inpatients in Ethiopia: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Pooled it
- Impact of the COVID-19 pandemic on surgical outcomes in patients undergoing colorectal cancer surgery: A retrospective study and meta-analysis of data from 11,082 participants.Frontiers in public health · 2022Pooled it
- Economic evaluation of programs against COVID-19: A systematic review.International journal of surgery (London, England) · 2021Pooled it
- Ramping Up Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement From The Society of Thoracic Surgeons COVID-19 Task Force.The Annals of thoracic surgery · 2020Guideline
- Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression.Journal of managed care & specialty pharmacy · 2022Trial
- Development and Validation of an Electronic Health Record-Derived Prediction Model for Preventing COVID-19 Hospitalization and Death.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- COVID-19-Related Healthcare Utilization and Costs in a Large Insured US Population, 2021-2025.Applied health economics and health policy · 2026Observational
- Cost-effectiveness and cost-utility of COVID-19 vaccination in a South African privately insured population: a real-world claims-based analysis.BMC health services research · 2026Article
- Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.Open forum infectious diseases · 2026Article
- The association of empirical treatment with oseltamivir with the outcome of critically ill patients admitted with severe acute respiratory illness (SARI).SAGE open medicine · 2026Article
- Estimating the direct medical cost of illness of COVID-19 hospitalisations in Kuwait: efficiency trade-offs from real-world data analysis.Health economics review · 2025Article
- Prevention, Detection, and Management of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.Gut and liver · 2025Review
- Long COVID Disproportionately Reported by Disadvantaged Individuals: A National Survey of U.S. Working-Age Adults.Journal of general internal medicine · 2025Article
- Adjusting hospital reimbursements to the onset of a new disease: Lesson from Covid-19.Health policy OPEN · 2025Article
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
With the coronavirus disease 2019 (COVID-19) pandemic, one of the major concerns is the direct medical cost and resource use burden imposed on the US health care system. We developed a Monte Carlo simulation model that represented the US population and what could happen to each person who got infected. We estimated resource use and direct medical costs per symptomatic infection and at the national level, with various "attack rates" (infection rates), to understand the potential economic benefits of reducing the burden of the disease. A single symptomatic COVID-19 case could incur a median direct medical cost of $3,045 during the course of the infection alone. If 80 percent of the US population were to get infected, the result could be a median of 44.6 million hospitalizations, 10.7 million intensive care unit (ICU) admissions, 6.5 million patients requiring a ventilator, 249.5 million hospital bed days, and $654.0 billion in direct medical costs over the course of the pandemic. If 20 percent of the US population were to get infected, there could be a median of 11.2 million hospitalizations, 2.7 million ICU admissions, 1.6 million patients requiring a ventilator, 62.3 million hospital bed days, and $163.4 billion in direct medical costs over the course of the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.